Biomarker for lung cancer diagnosis and use thereof

RNA sequencing identifies GREM1 and GAS6 as distinct markers for CAFs in NSCLC, enabling accurate diagnosis and treatment by measuring their expression levels, addressing the lack of specific CAF markers in NSCLC.

KR103046095B1Active Publication Date: 2026-11-10SAMSUNG LIFE PUBLIC WELFARE FOUND
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
KR1020250108296
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Priority Date
2024-09-04
Filing Date
2025-08-06
Publication Date
2026-11-10
Estimated Expiration
2045-08-06

AI Technical Summary

Technical Problem

There is a lack of specific markers for cancer-associated fibroblasts (CAFs) in non-small cell lung cancer (NSCLC), limiting accurate identification and understanding of their role in tumor progression and metastasis, and existing markers are shared across different cell types.

Method used

The use of RNA sequencing to identify distinct markers, specifically GREM1 and GAS6, for high-expression fibroblasts, which are then measured using agents like antibodies, oligopeptides, ligands, PNA, or aptamers to diagnose lung cancer and screen drugs.

Benefits of technology

GREM1 and GAS6-high-expressing fibroblasts are effective biomarkers for diagnosing NSCLC and can be targeted to treat the cancer by inhibiting their expression, providing a diagnostic and therapeutic approach.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112025089451682-PAT00004_ABST
    Figure 112025089451682-PAT00004_ABST
Patent Text Reader

Abstract

The present invention relates to a biomarker for diagnosing non-small cell lung cancer and its use. Specifically, it was confirmed that the diagnostic efficiency of lung cancer is excellent by measuring the levels of cancer-associated fibroblasts with high expression of GREM-1 and GAS6 in biological samples from patients; thus, the levels of said biomarkers can be measured and utilized for the prevention, improvement, and / or treatment of lung cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] One example of the present invention relates to a biomarker for diagnosing lung cancer and its use. Background Technology

[0002] Cancer-associated fibroblasts (CAFs) are a major component of the tumor stroma and are also known as peritumoral fibroblasts. CAFs play a crucial role in promoting tumor growth and progression through various mechanisms, including the secretion of growth factors, chemokines, and extracellular vesicles, as well as participation in the reorganization of the extracellular matrix (ECM). Through these modulations, they effectively regulate key aspects of tumor behavior, such as tumor proliferation, metastatic potential, chemotherapy resistance, immune evasion, and reactivation from a dormant state.

[0003] Since CAF was first identified, advancements in immunohistochemical methods and single-cell RNA sequencing have redefined existing CAF markers, such as platelet-derived growth factor receptor-α / β, α-smooth muscle actin (αSMA), fibroblast-activated protein (FAP), and fibroblast-specific protein-1. However, these proteins are also found in various immune cells and some cancer cells. A technical challenge in isolating CAF is the lack of specific markers, as most known markers are shared across different cell types. For example, podoplanin is expressed in lymphangiectatic cells, FAP in macrophages, and αSMA in smooth muscle cells.

[0004] These aspects highlighted the need for a set of subtype-specific markers distinct from normal fibroblasts (NF) to accurately identify various CAF populations. Furthermore, while CAF markers have been studied across many cancer types, research focused on non-small cell lung cancer (NSCLC) is rare, and information regarding NSCLC-specific CAF markers is limited. Moreover, the relationship and function between CAFs at metastatic and primary sites remain unclear. Prior art literature

[0006] Korean Patent Publication No. 10-2014-7008058 The problem to be solved

[0007] One aspect provides a composition for diagnosing lung cancer comprising a preparation for measuring the levels of GREM1 (Gremlin 1) and GAS6 (Growth Arrest Specific 6) high-expression fibroblasts.

[0008] Another aspect is to provide a lung cancer diagnostic kit comprising the above composition.

[0009] Another aspect is to provide a method for providing information regarding the diagnosis of lung cancer, comprising the step of measuring the levels of GREM-1 and GAS6 high-expression fibroblasts in biological samples isolated from an individual.

[0010] Another aspect is the step of measuring GREM-1 and GAS6 high-expression fibroblast levels in isolated biological samples; the step of contacting the biological samples with a test substance;

[0011] The present invention provides a method for screening drugs for lung cancer treatment, comprising: a step of measuring the levels of GREM-1 and GAS6 high-expression fibroblasts in a biological sample after contact with the test substance; and a step of determining the test substance as a drug for lung cancer treatment if the levels of GREM-1 and GAS6 high-expression fibroblasts in the biological sample decrease. means of solving the problem

[0012] The inventors used RNA sequencing to perform an analysis to distinguish distinct markers representing CAF compared to NF in the context of non-small cell lung cancer under various conditions.

[0013] The present invention relates to fibroblasts with high expression of GREM-1 and GAS6. The inventors used RNA sequencing to perform an analysis to distinguish distinct markers representing CAF compared to NF in the context of non-small cell lung cancer under various conditions.

[0014] The present invention provides a composition for diagnosing lung cancer comprising a preparation for measuring the levels of GREM1 (Gremlin 1) and GAS6 (Growth Arrest Specific 6) high-expression fibroblasts.

[0015] In one embodiment of the present invention, the fibroblasts may be cancer-associated fibroblasts.

[0016] In one embodiment of the present invention, the agent for measuring the fibroblast level may be one or more selected from the group consisting of antibodies, oligopeptides, ligands, PNA (peptide nucleic acid), and aptamers that specifically bind to fibroblasts with high expression of GREM-1 and GAS6.

[0017] In one embodiment of the present invention, the lung cancer may be non-small cell lung cancer.

[0018] In addition, the present invention provides a lung cancer diagnostic kit comprising the above composition.

[0019] In addition, the present invention provides a method for providing information regarding the diagnosis of lung cancer, comprising the step of measuring the levels of GREM-1 and GAS6 high-expression fibroblasts in a biological sample isolated from an individual.

[0020] In one embodiment of the present invention, the method may further include the step of determining that partial non-small cell lung cancer has developed or is highly likely to develop if the levels of GREM-1 and GAS6 high-expression fibroblasts in the biological sample isolated from the individual have increased compared to a normal control sample.

[0021] In one embodiment of the present invention, the biological sample is whole blood, plasma, serum, sputum, tears, mucus, nasal washes, nasal aspirate, breath, urine, semen, saliva, peritoneal washings, ascites, cystic fluid, meningeal fluid, amniotic fluid, glandular fluid, pancreatic fluid, lymph fluid, pleural fluid, nipple aspirate, bronchial aspirate, bronchial washing fluid, bronchoalveolar lavage fluid, synovial fluid, joint aspirate, tracheal secretion (organ It can be secretions), cells, cell extracts, or cerebrospinal fluid.

[0022] In addition, the present invention comprises the steps of: measuring the levels of GREM-1 and GAS6 high-expression fibroblasts in a separated biological sample; and contacting a test substance with the biological sample.

[0023] The present invention provides a method for screening drugs for lung cancer treatment, comprising: a step of measuring the levels of GREM-1 and GAS6 high-expression fibroblasts in a biological sample after contact with the test substance; and a step of determining the test substance as a drug for lung cancer treatment if the levels of GREM-1 and GAS6 high-expression fibroblasts in the biological sample decrease.

[0024] In one embodiment of the present invention, the step of measuring the fibroblast level may be to measure the level of cancer-associated fibroblasts that express GREM-1 and GAS6. Effects of the invention

[0025] A lung cancer diagnostic composition comprising a preparation for measuring the levels of GREM-1 and GAS6-high-expressing fibroblasts according to a specific pattern has confirmed that GREM-1 and GAS6-high-expressing fibroblasts are effective as pathological biomarkers for the diagnosis of non-small cell lung cancer, and can effectively diagnose lung cancer using this, and furthermore, can effectively treat lung cancer by inhibiting GREM-1 and GAS6-high-expressing fibroblasts according to the diagnosis. Brief explanation of the drawing

[0026] Figures 1a to 1c show differentially expressed genes (DEGs) between CAF and NF. Figure 1a shows a heatmap of 74 DEGs. Figure 1b shows a volcano diagram. Figure 1c shows a heatmap of previously known fibroblast marker genes. Figures 2a through 2d show DEGs exhibiting differences in expression levels between CAF and NF. Figure 2a shows a heatmap of selected DEGs comparing CAF and NF. Figure 2b shows a box plot of DEGs comparing CAF and NF. Corrected p-values ​​(FDR, false discovery rate) considering multiple comparisons in a generalized linear model are used. COL11A1 and TNC are known fibroblast markers, while GREM1 belongs to the BMP pathway, CD36 to the antigen processing machinery pathway, CXCL2 to the chemokine pathway, and GAS6 to the hypoxia pathway. Figure 2c shows a box plot of DEGs comparing lymph node CAF (LN-CAF), lung CAF (Lung-CAF), and NF. Figure 2d shows the Western blot analysis of GREM-1 and GAS6 in LN-CAF, Lung-CAF, and NF derived from squamous cell carcinoma, adenocarcinoma, and non-neoplastic lung. Figures 3a through 3c illustrate pathways (gene sets) that show differences in expression between CAF and NF. Figure 3a calculates GSVA (gene set variation analysis) scores for each pathway in well-known databases (e.g., HALLMARK, BIOCARTA, KEGG, REACTOME, WIKI pathways) and displays a heatmap of selected pathways with significant differences in GSVA scores between CAF and NF. Figure 3b shows a box plot of GSVA scores for the selected pathways compared between CAF and NF. Figure 3c shows a box plot of GSVA scores for the selected pathways compared between LN-CAF, Lung-CAF, and NF. Figures 4a through 4c represent CAF subpopulation predictions. Figure 4a shows a heatmap of the CAF subpopulation based on GSVA scores. Figure 4b shows a box plot of GSVA scores for the CAF subpopulation comparing CAF and NF. Figure 4c shows a box plot of GSVA scores for the CAF subpopulation comparing LN-CAF, Lung-CAF, and NF. Figures 5a and 5b illustrate the M2 polarization of macrophages induced by CAF and the reversal effect through inhibition of GAS6 or GREM1. Figure 5a shows a schematic diagram of an experiment in which PMA-induced M0 macrophages were co-cultured with CAF or siRNA-treated CAF in a trans-well system at a 5:1 ratio. Figure 5b shows the results of RT-qPCR analysis on M1 (CD80, IL-6) and M2 (CD206, IL-10) marker expression in M0 macrophages after 3 days of co-culture with CAF derived from primary lung tumors or metastatic lymph nodes. Specific details for implementing the invention

[0027] The present invention provides a composition for diagnosing or predicting the prognosis of lung cancer, comprising a preparation for measuring the levels of GREM-1 and GAS6-high-expression fibroblasts.

[0028] In the present invention, "GREM-1" is a protein known as an antagonist of bone morphogenetic proteins (BMPs), and its expression may be increased in cancer-associated fibroblasts.

[0029] In the present invention, "GAS6" is a protein secreted by cancer-associated fibroblasts, and its expression may be increased in cancer-associated fibroblasts.

[0030] In the present invention, "high expression" means an increase in the expression of a biomarker compared to a general control group. For example, it may mean a case where the expression of a biomarker in a sample increases by 1.2 times, 1.3 times, 1.4 times, 1.5 times, 1.8 times, 2.0 times, 2.5 times, 3.0 times, 5.0 times, or 10.0 times or more.

[0031] In the present invention, "fibroblasts" refer to cells that are mainly located in the dermis layer of the skin and produce collagen, hyaluronic acid, elastin, etc. The present invention provides a composition for diagnosing lung cancer comprising a preparation for measuring the levels of fibroblasts with high expression of GREM-1 and GAS6.

[0032] In the present invention, "GREM-1 (Gremlin 1)" is a protein known as an antagonist of bone morphogenetic proteins (BMPs), and its expression may be increased in cancer-associated fibroblasts.

[0033] In the present invention, "GAS6 (Growth Arrest Specific 6)" is a protein secreted by cancer-associated fibroblasts, and its expression may increase in cancer-associated fibroblasts.

[0034] In the present invention, "high expression" means an increase in the expression of a biomarker compared to a general control group. For example, it may mean a case where the expression of a biomarker in a sample increases by 1.2 times, 1.3 times, 1.4 times, 1.5 times, 1.8 times, 2.0 times, 2.5 times, 3.0 times, 5.0 times, or 10.0 times or more.

[0035] In this invention, "fibroblasts" are primarily located in the dermis layer of the skin and play an important role in maintaining skin health and elasticity by producing collagen, hyaluronic acid, elastin, etc. Unlike cancer-associated fibroblasts, normal fibroblasts do not perform tumor-promoting functions and do not accelerate cancer progression. Furthermore, normal fibroblasts do not suppress the immune response; rather, they support normal immune functions.

[0036] In this invention, "cancer-associated fibroblasts" refer to cells that play an important role in the tumor microenvironment, exist within cancer tissue, and have a significant influence on the evolution of cancer.

[0037] In one embodiment of the present invention, methods for measuring or comparing the level of fibroblasts include, but are not limited to, protein chip analysis, immunoassay, ligand binding assay, MALDI-TOF (Matrix Assisted Laser Desorption / Ionization Time of Flight Mass Spectrometry) analysis, SELDI-TOF (Surface Enhanced Laser Desorption / Ionization Time of Flight Mass Spectrometry) analysis, radioimmunoassay, radioimmunodiffusion, Ouchteroni immunodiffusion, Rocket immunoelectrophoresis, tissue immunostaining, complement fixation assay, two-dimensional electrophoresis analysis, liquid chromatography-mass spectrometry (LC-MS), LC-MS / MS (liquid chromatography-mass spectrometry / mass spectrometry), Western blotting, and ELISA (enzyme-linked immunosorbent assay).

[0038] In one embodiment of the present invention, the fibroblasts may be cancer-associated fibroblasts.

[0039] In one embodiment of the present invention, the agent for measuring the fibroblast level may be one or more selected from the group consisting of antibodies, oligopeptides, ligands, PNA (peptide nucleic acid), and aptamers that specifically bind to fibroblasts with high expression of GREM-1 and GAS6.

[0040] In this specification, "antibody" refers to a substance that specifically binds to an antigen and causes an antigen-antibody reaction. For the purposes of the present invention, it may be an antibody that binds to high-expression IL-1ß macrophages. The antibodies of the present invention include polyclonal antibodies, monoclonal antibodies, and recombinant antibodies. The antibodies can be easily manufactured using techniques widely known in the art. Furthermore, the antibodies of the present invention include not only a complete form having two full-length light chains and two full-length heavy chains, but also functional fragments of the antibody molecule. A functional fragment of the antibody molecule means a fragment possessing at least an antigen-binding function, such as Fab, F(ab'), F(ab')2, and Fv.

[0041] In this specification, "PNA (Peptide Nucleic Acid)" refers to an artificially synthesized polymer similar to DNA or RNA, which was first introduced in 1991 by Professors Nielsen, Egholm, Berg and Buchardt of the University of Copenhagen, Denmark. While DNA has a phosphate-ribose sugar backbone, PNA has a repeating N-(2-aminoethyl)-glycine backbone connected by peptide bonds, which significantly increases its binding affinity and stability to DNA or RNA, and is therefore used in molecular biology, diagnostic analysis, and antisense therapy.

[0042] In this specification, the term "aptamer" refers to an oligonucleotide or peptide molecule and signifies a ligand-specific DNA or RNA molecule having high affinity for proteins. An aptamer is a single-stranded DNA or RNA molecule that possesses the ability to bind specifically to a particular substance and has a unique tertiary structure of its own. It can be mass-produced in a short time and at low cost using chemical synthesis techniques and has excellent advantages in terms of productivity due to minimal batch-to-batch variation. Furthermore, due to its high stability against changes in the surrounding environment, such as pH or temperature, its potential for application in various fields, such as the detection of target substances and the development of disease diagnostic sensors, is highly regarded.

[0043] In one embodiment of the present invention, the lung cancer may be non-small cell lung cancer. In this case, “non-small cell lung cancer” (NSCLC) is a collective term for all epithelial lung cancers excluding small cell lung cancer, and refers to lung cancer that accounts for about 85% of all lung cancers and includes major subtypes such as adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.

[0044] In the present invention, the "diagnosis" includes determining the susceptibility of a subject to a specific disease or condition, determining whether the subject currently has a specific disease or condition, determining the prognosis of a subject with a specific disease or condition (e.g., identification of a pre-metastatic or metastatic cancer state, determination of the stage of cancer, or determination of the responsiveness of cancer to treatment), or therametrics (e.g., monitoring the condition of the subject to provide information on therapeutic efficacy). For the purposes of the present invention, the diagnosis is to determine whether the said disease has occurred or the likelihood (risk) of its occurrence, the said cancer stage, or the survival rate or responsiveness of the cancer patient.

[0045] In the present invention, the term "stage" refers to the extent of cancer cell spread or the stage of cancer progression, and the international classification based on the progression of cancer generally follows the TNM staging system. Here, 'T (Tumor Size)' is a classification based on the size of the primary tumor, 'N (Lymph Node)' is a classification based on the extent of lymph node metastasis, and 'M (Metastasis)' corresponds to a classification based on whether metastasis to other organs has occurred.

[0046] In addition, the present invention provides a lung cancer diagnostic kit comprising the above composition.

[0048] In addition, the present invention provides a method for providing information regarding the diagnosis of lung cancer, comprising the step of measuring the levels of GREM-1 and GAS6 high-expression fibroblasts in a biological sample isolated from an individual.

[0049] In this specification, the term "individual" refers to all living organisms, including humans, rats, mice, livestock, etc. Specific examples may include mammals, including humans.

[0050] In one embodiment of the present invention, the method may further include the step of determining that non-small cell lung cancer has developed or is highly likely to develop if the levels of GREM-1 and GAS6 high-expression fibroblasts in a biological sample isolated from the individual have increased compared to a normal control sample.

[0051] In one embodiment of the present invention, the biological sample is whole blood, plasma, serum, sputum, tears, mucus, nasal washes, nasal aspirate, breath, urine, semen, saliva, peritoneal washings, ascites, cystic fluid, meningeal fluid, amniotic fluid, glandular fluid, pancreatic fluid, lymph fluid, pleural fluid, nipple aspirate, bronchial aspirate, bronchial washing fluid, bronchoalveolar lavage fluid, synovial fluid, joint aspirate, tracheal secretion (organ It can be secretions), cells, cell extracts, or cerebrospinal fluid.

[0052] In addition, the present invention comprises the steps of: measuring the levels of GREM-1 and GAS6 high-expression fibroblasts in a separated biological sample; and contacting a test substance with the biological sample.

[0053] The present invention provides a method for screening drugs for lung cancer treatment, comprising: a step of measuring the levels of GREM-1 and GAS6 high-expression fibroblasts in a biological sample after contact with the test substance; and a step of determining the test substance as a drug for lung cancer treatment if the levels of GREM-1 and GAS6 high-expression fibroblasts in the biological sample decrease.

[0054] In this specification, "treatment" may mean any act in which the symptoms of lung cancer in an individual are improved or beneficially altered by the administration of a pharmaceutical composition according to one aspect.

[0055] In one embodiment of the present invention, the step of measuring the fibroblast level may be to measure the level of cancer-associated fibroblasts that express GREM-1 and GAS6.

[0057] The present invention will be explained in more detail below through examples. However, these examples are intended to illustrate the invention and the scope of the invention is not limited to these examples.

[0059] Examples and Experimental Examples

[0060] 1. Experimental Method

[0061] (1) Isolation and culture of CAF and NF

[0062] The isolation and culture of CAF and NF were performed as described in the previous report. Briefly, CAF was isolated from tumor tissue (primary tumor or metastatic lymph nodes), and NF was isolated from non-tumor tissue furthest from the tumor in the resected lungs of NSCLC patients. Non-tumor and tumor specimens were washed three times with phosphate-buffered saline (PBS; HyClone, Logan, UT, USA). Tissue specimens were chopped into 1-2 mm pieces and dissociated using 1 mL of 0.25% collagenase type I (STEMCELL Technologies, Vancouver, Canada) in a 37°C incubator for 30 minutes to 1 hour. The enzymatically dissociated tissue samples were centrifuged at 1300 rpm for 3 minutes. The pellet was resuspended in DMEM / F12 (Gibco, Invitrogen, Carlsbad, CA, USA), 10% fetal bovine serum (FBS; Gibco), and 1% antibiotic-antifungal solution (Gibco). Next, the pellet was cultured in 100 mm culture dishes. Cells were extended cultured for 7–14 days until 90% fusion was reached. Cells migrated from seeded tissue fragments were collected after trypsin-EDTA (Gibco) treatment. The collected cells were passed through a 100 μm filter (Falcon, Franklin Lakes, NJ, USA) and dispensed into 100 mm culture dishes. The cells were then extended to three passages and cryopreserved in full DMEM containing 10% dimethyl sulfoxide (Sigma-Aldrich, St. Louis, MO, USA) until analysis. CAF was verified by negative expression of EpCAM or E-cadherin via flow cytometry or RT-PCR.

[0064] (2) RNA sequencing analysis

[0065] Total RNA was extracted from cultured cell pellets of CAF or NF using the RNeasy Mini Kit (Qiagen). Nucleic acid extraction was performed according to the manufacturer's instructions. The quality and quantity of the extracted nucleic acids were evaluated using a Nanodrop 8000 UV-Vis spectrophotometer (NanoDrop Technologies Inc.), a Qubit® 3.0 fluorescence meter (Life technologies, Inc.), and a 4200 TapeStation (Agilent Technologies, Inc.). Sequencing libraries were prepared using the TruSeq RNA Sample Preparation Kit v2 (Illumina, Inc.) according to the manufacturer's protocol. Paired-end sequencing of the RNA libraries was performed on the HiSeq 2500 sequencing platform (Illumina, Inc.). After removing low-quality nucleotides from the FASTQ file, sequencing reads were aligned to the human reference genome (hg19) using STAR v2.5.2b, and gene expression was estimated by calculating the expected count using RSEM v1.3.

[0067] (3) Differential expression and gene set enrichment analysis

[0068] To compare gene expression levels between CAF and NF, differential expression (DE) analysis was performed using generalized linear modeling with the glmFit function of the R package edgeR v3.36.1. Batch effects based on tissue origin (lung or lymph node) were corrected for expression count values ​​using the design matrix within the R package edgeR. Significant DE genes were selected according to the following criteria: FDR-adjusted p-value < 0.05, logCPM > 2, and absolute value of log-fold change (log2 fold change, logFC) > 1. K-means-based clustering was performed on the expression profiles of significant DE genes, and heatmaps were generated using the R package ComplexHeatmap v2.10.0. For gene set enrichment analysis, GSVA scores were calculated for each gene set (pathway) using the R package GSVA v1.42.0 against the HALLMARK, C2 (curation), and C6 (oncolytic) gene set (pathway) databases of the R package MSigDB v7.4.1. Gene sets were considered to represent significant DEs according to the following criteria: an absolute value of log2 fold change (logFC) > 0.4 and an FDR-adjusted p-value < 0.05 by nonparametric (e.g., Kruskal-Wallis) tests. For pairwise comparisons, t-tests were performed, and statistical significance was determined by the FDR-adjusted p-value.

[0070] (4) CAF subgroup prediction

[0071] To decode CAF into three subgroups (myCAF, iCAF, apCAF), GSVA scores were estimated based on a specific set of genes reported in pancreatic cancer using the GSVA R package (v1.42.0). myCAF with lung cancer annotations was also estimated as a GSVA score based on high-expression genes (COL4A1, ACTA2, MEF2C, MYG11, ITGA7). Differences in GSVA scores between CAF subgroups were analyzed using the Kruskal-Wallis test. The threshold for statistical significance was an FDR-adjusted p-value < 0.05.

[0073] (5) Western Blot

[0074] Cells were harvested and suspended in lysis buffer (150 mM NaCl, 25 mM Tris-Cl, pH 7.4, 1% NP-40, 10 mM EDTA) containing a protease inhibitor cocktail (Roche, Mannheim, Germany). After boiling for 10 minutes, the cell lysate was centrifuged at 13,000 rpm for 10 minutes at room temperature (RT). The protein sample was quantified in the cells using modified BCA protein assay reagent (Pierce, cat. no. 23228). A volume of 20 μg of the protein sample was electrophoresed on a 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gradient gel and transferred to a PVDF membrane (Bio-Rad, Hercules, CA, USA) using a Trans-Blot electrophoresis cell transfer system (Bio-Rad Laboratories, Hercules, CA, USA). The protein-transferred PVDF membrane was reacted for 1 hour in 5% BSA in 1X TBST (150 mM NaCl, 50 mM Tris-Cl, pH 7.5, 0.1% Tween 20), washed with 1X TBST, and then reacted overnight at 4°C with a primary antibody diluted 1:500 in TBST containing 5% BSA. Detection was performed using a chemiluminescent substrate (Thermo Fisher) followed by exposure to ECL solution (Thermo Fisher, 34094). Western blots were performed by applying primary antibodies against GAS6 (Abcam, ab264098), GREM1 (R&D Systems, AF956), α-SMA (Abcam, ab7817), and β-actin (Santa Cruz, sc-47778) to the blot at a 1:500 ratio.

[0076] 2. Experimental Results

[0077] (1) Patient characteristics

[0078] Twenty-two cancer-associated fibroblast (CAF) samples and eleven normal fibroblast (NF) samples were included in the study from 22 patients with non-small cell lung cancer (NSCLC). The 22 CAF samples consisted of 12 adenocarcinomas and 10 squamous cell carcinomas (SqCC): 16 originated from primary tumors and 6 from metastatic lymph nodes. Additionally, 12 samples originated from stage I or II cancer, and 10 samples from stage III or IV cancer. The eleven NF samples included eight adenocarcinomas and three SqCCs, all originating from non-neoplastic lungs. Ten pairs of CAF and NF were isolated from the same patient.

[0080] (2) Analysis of genes expressed differently between CAF and NF

[0081] Figure 1 showed the DEGs between CAF and NF using 22 CAF samples and 11 NF samples. Figure 1a shows a heatmap of 74 DEGs, which clearly distinguished CAF from NF and lymph node-derived CAF (LN-CAF) from lung-derived CAF (Lung-CAF) during unsupervised clustering. A volcano plot indicated 66 genes (e.g., GAS6, GREM1, CD36, COL11A1, IGF2) and 8 genes (e.g., TNC, CXCL2, MMP1) that were significantly upregulated in CAF (Figure 1b). Figure 1c shows a heatmap of significant DEGs of known fibroblast markers, which also clearly distinguished CAF from NF and LN-CAF from Lung-CAF.

[0083] Figure 2 showed six genes (GAS6, GREM1, CD36, COL11A1, TNC, CXCL2) among the DEGs between CAF and NF: COL11A1 and TNC (fibroblast markers), GREM1 (bone morphogenetic protein [BMP] pathway), CD36 (antigen processing machinery pathway), CXCL2 (chemokine pathway), and GAS6 (hypoxia pathway). Figure 2a shows the heatmap of these DEGs, clearly distinguishing CAF from NF and LN-CAF from Lung-CAF. COL11A1, GREM1, CD36, and GAS6 were significantly high in CAF, while TNC and CXCL2 showed high levels in NF (all FDRs, p≤ 0.0001) (Figure 2b). COL11A1 expression was higher in Lung-CAF than in LN-CAF or NF (FDR, p ≤ 0.0001) (Fig. 2C). CD36 expression was highest in LN-CAF and exceeded the levels of Lung-CAF and NF (all FDRs, p ≤ 0.0001). CXCL2 expression was higher in LN-CAF than in Lung-CAF but lower than in NF (all FDRs, p ≤ 0.0001). Both GREM1 and GAS6 showed strong expression in Lung-CAF and LN-CAF compared to NF (all FDRs, p ≤ 0.0001) (Fig. 2C). Western blot analysis also showed that protein expression of GREM1 and GAS6 was higher in both LN-CAF and Lung-CAF compared to NF, regardless of histological subtype (Fig. 2d).

[0085] (3) Gene set enrichment analysis between CAF and NF

[0086] Figure 3a shows a heatmap of Gene Set Variation Analysis (GSVA) ​​scores for selected gene sets comparing CAF and NF. The GSVA scores clearly distinguished CAF from NF but did not completely distinguish LN-CAF from Lung-CAF. Gene sets related to Hallmark Hypoxia and EMT (Epithelial-Mesenchymal Transition) were upregulated in CAF compared to NF (all FDRs, p ≤ 0.0001) (Figure 3b). Conversely, gene sets related to Reactome Mismatch Repair showed significantly higher GSVA scores in NF than in CAF (FDR, p ≤ 0.0001). Additionally, LN-CAF showed higher GSVA scores in gene sets such as Hallmark Hypoxia and Hallmark EMT compared to Lung-CAF (FDR, p ≤ 0.0001) (Figure 3c).

[0088] (4) CAF subgroup analysis

[0089] Figure 4a shows heatmaps of CAF and NF subgroups based on previously reported gene sets, which clearly distinguished CAF from NF but did not completely distinguish LN-CAF from Lung-CAF. CAF showed significantly higher GSVA scores for the myofibroblast CAF (myCAF) subgroup compared to NF (FDR, p ≤ 0.0001), and NF showed significantly higher GSVA scores for the antigen-presenting CAF (apCAF) subgroup compared to CAF (FDR, p ≤ 0.01). GSVA scores for the inflammatory CAF (iCAF) subgroup were similar between CAF and NF (Figure 4b). Both Lung-CAF and LN-CAF showed significantly higher GSVA scores for the myCAF subgroup compared to NF (all FDRs, p ≤ 0.0001), and NF showed significantly higher GSVA scores for the apCAF subgroup compared to Lung-CAF (FDR, p ≤ 0.01) (Fig. 4c). Additionally, LN-CAF and NF showed significantly higher GSVA scores for the iCAF subgroup compared to Lung-CAF (all FDRs, p ≤ 0.05).

[0091] (5) Induction of macrophage polarization by CAF-derived signals

[0092] Figure 5a shows a schematic diagram of an experiment in which CAF derived from non-small cell lung cancer patients and M0 macrophages induced by PMA (phorbol 12-myristate 13-acetate) were co-cultured for 3 days using a trans-well system. The CAF was compared with CAFs introduced with siRNA targeting GREM1 or GAS6. RT-qPCR analysis revealed that the expression of both M1 macrophage markers (CD80 and IL-6) and M2 macrophage markers (CD206 and IL-10) increased in all CAF samples (Figure 5b). However, when co-cultured with CAFs in which GREM1 or GAS6 was inhibited, the expression of M2 markers (CD206 and IL-10) was significantly reduced, while the decrease in M1 marker expression was inconsistent.

[0094] Accordingly, through this embodiment, it was confirmed that cancer-associated fibroblasts derived from non-small cell lung cancer patients specifically upexpress multiple genes, including GREM1 and GAS6, compared to normal fibroblasts, and that the expression of said genes is associated with increased activity of a set of genes related to hypoxic response and epithelial-mesenchymal transition. Furthermore, it was confirmed that fibroblasts with high expression of GREM1 and GAS6 are involved in immunomodulation within the tumor microenvironment by inducing M2-like phenotype polarization in macrophages. Accordingly, by measuring the levels of fibroblasts with high expression of GREM1 and GAS6, it is possible to provide a composition and kit usable for lung cancer diagnosis, and it was confirmed that this can also be applied as a drug screening method to evaluate the efficacy of substances targeting said fibroblasts.

[0096] The foregoing description of the present invention is for illustrative purposes only, and those skilled in the art will understand that other specific forms can be easily modified without altering the technical spirit or essential features of the present invention. Therefore, the embodiments described above should be understood as illustrative in all respects and not restrictive.

Claims

Claim 1 A composition for diagnosing lung cancer comprising a preparation for measuring the levels of GREM-1 (Gremlin 1) and GAS6 (Growth Arrest Specific 6) high-expression fibroblasts, wherein the fibroblasts are cancer-associated fibroblasts and the lung cancer is non-small cell lung cancer (NSCLC). Claim 2 delete Claim 3 The composition of claim 1, wherein the preparation for measuring fibroblast levels is one or more selected from the group consisting of antibodies that specifically bind to GREM-1 and GAS6 high-expression fibroblasts, oligopeptides, ligands, PNA (peptide nucleic acid), and aptamers. Claim 4 delete Claim 5 A lung cancer diagnostic kit comprising the composition of either claim 1 or 3. Claim 6 A method for providing information regarding the diagnosis of lung cancer, comprising the step of measuring the levels of GREM-1 (Gremlin 1) and GAS6 (Growth Arrest Specific 6) high-expression fibroblasts in a biological sample isolated from an individual, wherein the fibroblasts are cancer-associated fibroblasts and the lung cancer is non-small cell lung cancer (NSCLC). Claim 7 A method for providing information according to claim 6, further comprising the step of determining that non-small cell lung cancer has developed or is highly likely to develop if the levels of GREM-1 and GAS6 high-expression fibroblasts in a biological sample isolated from the individual have increased compared to a normal control sample. Claim 8 In claim 6, the biological sample is whole blood, plasma, serum, sputum, tears, mucus, nasal washes, nasal aspirate, breath, urine, semen, saliva, peritoneal washings, ascites, cystic fluid, meningeal fluid, amniotic fluid, glandular fluid, pancreatic fluid, lymph fluid, pleural fluid, nipple aspirate, bronchial aspirate, bronchial washing fluid, bronchoalveolar lavage fluid, synovial fluid, joint aspirate, tracheal secretion (organ A method of providing information, which is secretions), cells, cell extracts, or cerebrospinal fluid. Claim 9 A drug screening method for treating lung cancer comprising: a step of measuring the levels of GREM-1 (Gremlin 1) and GAS6 (Growth Arrest Specific 6) high-expression fibroblasts in a separated biological sample; a step of contacting a test substance with the biological sample; a step of measuring the levels of GREM-1 and GAS6 high-expression fibroblasts in the biological sample after contact with the test substance; and a step of determining the test substance as a drug for treating lung cancer if the levels of GREM-1 and GAS6 high-expression fibroblasts in the biological sample decrease; wherein the fibroblasts are cancer-associated fibroblasts and the lung cancer is non-small cell lung cancer (NSCLC). Claim 10 delete

Citation Information

Patent Citations

  • Composition and method for treatment and diagnosis of lung cancer

    JP2010227112A

  • Compositions, methods and kits for diagnosis of lung cancer

    WO2019079635A1